Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.
about
Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy.Circulation of progenitor cells in obese and lean colorectal cancer patientsA new approach for rapid and reliable enumeration of circulating endothelial cells in patients.Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy.Imaging flow cytometry for morphologic and phenotypic characterization of rare circulating endothelial cells.A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients.Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma.Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma.Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study.Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumoursDiscrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy.The PCa Tumor Microenvironment.Human vascular endothelial cells: a model system for studying vascular inflammation in diabetes and atherosclerosis.Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy.Glutathione S-transferase P1 correlated with oxidative stress in hepatocellular carcinomaKDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression.Flow cytometric analysis of circulating endothelial cells and endothelial progenitors for clinical purposes in oncology: A critical evaluation.Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index.Blood-based biomarkers for the optimization of anti-angiogenic therapiesCirculating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma.Cell-based methods for ex vivo evaluation of human endothelial biology.New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.Isolating and defining cells to engineer human blood vessels.Human endothelial progenitor cells.Renalase, hypertension, and kidney - the discussion continues.Vascular remodeling in cancer.Tumor vascularity in prostate cancer: an update on circulating endothelial cells and platelets as noninvasive biomarkers.Circulating endothelial cells and their subsets: novel biomarkers for cancer.Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy.Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts.Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood.Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapiesCirculating endothelial cells and their progenitors in acute myeloid leukemia.Enumeration of circulating endothelial cell frequency as a diagnostic marker in aortic valve surgery - a flow cytometric approach.
P2860
Q33624863-B9A94044-20D6-40A8-9864-7BF56EB83F3CQ33796332-DB986CAE-CA70-4FDF-BD47-9BDC753BC5A9Q34183354-DBE71125-6639-4465-A8DA-E922C0B9606AQ34523039-22C256A5-BC4E-483A-B0A2-C18D95A30795Q34647525-36883F7D-65D5-4D3C-A60D-98D7DB298DCBQ34703792-36D05718-DCCD-4F35-AA36-3A7A0011F03FQ34762886-B2030E3C-B67A-4070-889A-452BA8433F76Q34999120-C2782F38-963C-49C5-A805-B5BF68C77006Q35108342-2FA95F06-8F5A-437D-97EA-1173D44CFF21Q35115634-F775860B-292D-4BD9-BA5F-C22A2C46BD88Q35155251-B34C9AF1-9E8B-41D3-BAF7-E9A845A88F2EQ35274974-F008F0D9-EA03-4F4A-9CC4-8CE198E8E2E5Q35444368-F1BC8ED1-B85B-432F-9636-B9C9EF82371BQ35603143-333D5BC8-FC9C-42C8-971B-ACCF76FB0E55Q35848911-87D42143-715E-4F1E-B2DA-F95092B105FAQ36286704-AAC98C5D-A57A-402E-A13B-122DF519D10CQ36342262-D20C35F1-E467-4E02-B78B-7E924651C41AQ36746926-7AA42D5F-2456-43C8-B248-EA34BA2019E7Q36805595-9010B1C1-FE8F-4BA1-ABC1-2FF9F80BFF79Q36831312-5182792F-FFD9-4C9B-B666-FBC17DF7DC79Q36954000-5E1A1156-A4FF-4EC4-96C7-B5DDF86DB504Q36998185-4E188BED-A467-49C2-B81D-7A21D9F6284FQ37129663-AF7BF5DD-25BC-4065-9AC3-87DA462808C4Q37269351-7CF8DD27-5EE4-4D8C-8F0D-619D53E16FF3Q37328390-4BA7104E-6686-4BDF-B5F7-BB939F56B723Q37463927-BEE54464-4959-449B-B4A2-9A7642178F5DQ37739010-F1ED9AB9-AD48-4CA9-8903-361DBC03E9AAQ37752435-FCCCF898-5611-42D2-8790-0C725A1E7080Q37863715-16039A73-E297-4631-9D09-6BD81A6966D8Q38023863-DD9B65C3-0FED-4729-BF54-6239DB793361Q38042591-EDC0018B-3B01-4343-BC9C-C6F1455D1BA2Q38126351-886B7FE9-9F47-4072-9160-AB1C5C324BB7Q38165245-006BEF3A-F37E-43A6-9C96-662BF8D33B47Q38672972-5BD1E3F5-40C7-4C36-B64C-CE3A78FBEAC3Q39263457-70938881-5D7C-465C-BFEA-3D0A4E6909A0Q39356122-93637C2A-A5E9-4356-92B2-26CBE10C2006Q40608911-FB667C3B-8B05-4A7D-9B07-384A6D673F09Q40751413-611EFB56-F626-4CA5-940C-503C38DF5629Q41153604-690C56F5-CFC4-48F2-8D93-49629BD1D4C6Q41337005-59F5AE48-A41C-42F0-B6FB-C11037B1239D
P2860
Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Validation of a standardized m ...... and ultrastructural analyses.
@en
Validation of a standardized m ...... and ultrastructural analyses.
@nl
type
label
Validation of a standardized m ...... and ultrastructural analyses.
@en
Validation of a standardized m ...... and ultrastructural analyses.
@nl
prefLabel
Validation of a standardized m ...... and ultrastructural analyses.
@en
Validation of a standardized m ...... and ultrastructural analyses.
@nl
P2093
P50
P1476
Validation of a standardized m ...... and ultrastructural analyses.
@en
P2093
Amado J Zurita
Angelica Calleri
Cristina Rabascio
David R Shalinsky
Hua-Kang Wu
Jessica Quarna
John B Cheng
Luca Saronni
Paola Braidotti
Patrizia Mancuso
P304
P356
10.1158/1078-0432.CCR-08-0432
P407
P577
2009-01-01T00:00:00Z